The recent discovery of the role of thrombopoietin (TPO) in managing the count of platelets has paved the way for better treatment options for Immune thrombocytopenia patients. The administration of TPO resulted in an increased quantity of the platelet count. Presently, the Immune thrombocytopenia Market consists of three FDA-approved TPO-RA therapies are Nplate (romiplostim), Promacta (eltrombopag), and Doptelet (avatrombopag). However, in Europe and Japan, only Nplate and Promacta are given recommendations from their respective regulatory authorities
https://www.delveinsight.com/blog/immune-